If you have seen a product called Tianaa, Zaza, Neptune's Fix, or TD Red at a gas station or smoke shop, you may not have known what you were looking at. These products contain tianeptine, a substance the U.S. Food and Drug Administration has not approved for any medical use. They are sold as "dietary supplements" or "mood boosters." That framing is dangerous and misleading.
Tianeptine acts on the same opioid receptors in the brain that heroin and fentanyl target. It produces a similar pattern of dependence, tolerance, and withdrawal. People who develop tianeptine use disorder frequently describe withdrawal as more severe than opioid withdrawal. The FDA has been tracking adverse events involving tianeptine since 2016, and in May 2025 issued a public health advisory warning clinicians about a growing surge in serious harm and death linked to these products.
This article explains what tianeptine is, how it affects the brain, what dependence and withdrawal look like, and what treatment options are available for people who want to stop using it.
Tianeptine is an atypical antidepressant that is approved in some countries in Europe and South America for treating major depressive disorder. It is not approved by the FDA for any use in the United States.
Tianeptine works differently from most antidepressants. At high doses, it binds to mu-opioid receptors, the same receptors activated by heroin, oxycodone, and fentanyl. This opioid-like action produces euphoria and sedation and creates a strong potential for physical dependence. Standard antidepressants do not work this way.
In the U.S., tianeptine is sold legally in many states under product names including:
These products are typically marketed as brain supplements, nootropics, or mood support products. They are available at gas stations, convenience stores, smoke shops, and online, which is why tianeptine has acquired the street name "gas station heroin."
As of June 2026, eleven states have banned tianeptine, including Alabama, Michigan, Mississippi, Tennessee, Georgia, Indiana, Ohio, Florida, Kentucky, Virginia, and North Carolina. Federal legislation to classify tianeptine and its analogues as Schedule III controlled substances under the Controlled Substances Act was reintroduced in Congress in May 2025. The substance currently has no federal scheduling in the U.S., which allows it to remain on shelves in states without bans.
Tianeptine is not detected on standard urine drug screening panels. A person who is dependent on it can be presenting with opioid withdrawal symptoms while their drug screen returns completely negative. Clinicians and families are often unaware of the substance, which delays recognition and treatment.
Tianeptine activates the mu-opioid receptor, the same receptor pathway responsible for addiction to heroin, fentanyl, oxycodone, and other opioids. The ASAM defines opioid use disorder as a chronic brain disease characterized by compulsive drug-seeking, loss of control over use, and continued use despite harm. Tianeptine use disorder fits that clinical definition.
When a person uses tianeptine repeatedly, the brain adapts by reducing the sensitivity of opioid receptors and reducing its own natural production of endorphins. This creates physical dependence: the brain now needs tianeptine to function normally. Stopping the drug triggers withdrawal.
Tolerance develops quickly with tianeptine. A person who starts using one bottle per day may escalate to several bottles within weeks in order to prevent withdrawal and maintain effect. This escalation pattern mirrors opioid use disorder closely, which is consistent with the FDA's case reports and peer-reviewed clinical literature published through 2025.
Dependence on tianeptine often goes unrecognized because the product looks like a legal supplement. Families and clinicians may not consider it a substance of concern.
Signs that a person may be struggling with tianeptine use disorder include:
Withdrawal from tianeptine can begin within hours of the last dose. People in tianeptine withdrawal describe the experience as more intense than opioid withdrawal in some cases, with prominent anxiety, agitation, and physical distress. Withdrawal lasts days and can require medical supervision to manage safely.
Anyone who encounters these products is at risk of developing dependence. Tianeptine is being sold openly in regions where it is not yet banned, and its marketing as a supplement masks the opioid-like risk.
Certain groups face elevated risk. Research published in 2025 in BMC Public Health identified several patterns:
The FDA noted in its 2025 advisory that tianeptine is not identified in routine drug screening, which means people may be actively dependent while their healthcare providers remain unaware.
Tianeptine use disorder is a treatable medical condition. It is not a moral failure. A person struggling with it is not weak or making a bad choice; their brain has developed a physical dependency that requires clinical support to address safely.
Because tianeptine activates opioid receptors, medications approved for opioid use disorder have shown clinical benefit in managing withdrawal and supporting recovery. These include:
Buprenorphine (Suboxone, Sublocade): Multiple peer-reviewed case reports published between 2019 and 2025 document successful use of buprenorphine to manage tianeptine withdrawal and support sustained recovery. Buprenorphine is a partial opioid agonist that reduces cravings and blocks opioid-like effects. It is available through office-based prescribers and, as of the DEA's January 2025 final rule, through telehealth providers without an initial in-person visit.
Naloxone: Because tianeptine activates opioid receptors, naloxone (Narcan) is effective as a reversal agent in overdose situations involving tianeptine. Anyone in a household where tianeptine use disorder is present should have naloxone on hand. It is available without a prescription at most pharmacies.
Supportive medications for withdrawal: Clinical case reports document the use of medications such as hydroxyzine and loperamide to manage tianeptine withdrawal symptoms when buprenorphine is not immediately initiated.
The appropriate level of care depends on the severity of dependence, the presence of co-occurring mental health conditions, and the individual's support system. Options along the ASAM continuum of care include:
Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI) are first-line behavioral treatments for substance use disorders across substances, including opioids. These approaches help a person identify the triggers that drive use, develop coping strategies, and build motivation for sustained recovery.
Peer support and recovery support services complement clinical treatment. Organizations like SMART Recovery and 12-step programs provide community and accountability alongside professional care.
If you believe a family member is struggling with tianeptine use disorder, the most important first step is to avoid stigmatizing the situation. Dependence on this substance developed through a pharmacological process, not through a character defect. Shame-based confrontations tend to increase isolation and delay treatment.
A direct, compassionate conversation focused on concern for the person's health is more productive. Offering to help them find a clinician or treatment program, and being willing to accompany them to an appointment, removes barriers that often prevent people from seeking help.
SAMHSA's National Helpline (1-800-662-4357) is available 24 hours a day, 7 days a week, and provides confidential referrals to local treatment providers. The helpline is free and available in English and Spanish.
Tianeptine overdose can cause respiratory depression, loss of consciousness, severely low blood pressure, prolonged QT interval, and cardiac events. Naloxone counteracts the opioid receptor component of a tianeptine overdose and should be administered immediately if overdose is suspected. Call 911 immediately after administering naloxone. Medical evaluation is required even if the person regains consciousness, because tianeptine also has non-opioid effects that naloxone does not reverse.
If you or someone you care about is using tianeptine and wants to stop, treatment is available and it works. Withdrawal from this substance is difficult and medically significant, which means trying to stop without professional support carries real risk. A clinician experienced in opioid use disorder treatment can guide the process safely.
The team at Struggling With Addiction can help you find accredited treatment providers near you. Use our Treatment Finder or call SAMHSA's helpline at 1-800-662-4357 to get connected to care today. You do not have to navigate this alone, and recovery is possible.
